Tyagarajan Seshu — SEC Form 4 filings
SEC reporting owner CIK 1923794. 12 Form 4 filings on record with FilingPulse; latest filed 2026-08-19.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-07-15 to 2026-08-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 9 filings — 153,996 shares, $1,197,703 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 31,278 shares @ $8.82 ($275,947) in Candel Therapeutics, Inc., filed 2025-03-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | Chief Technology Officer | 12 | — | 9 legs · 153,996 sh · $1,197,703 | 6 |
Form 4 filings — Tyagarajan Seshu
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 7,000 @ $12 | EDGAR |
| 2026-07-01 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 7,000 @ $10.02 | EDGAR |
| 2026-01-28 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 5,353 @ $4.67 | EDGAR |
| 2025-03-20 | 4/A | Candel Therapeutics, Inc. (CADL) | Option exercise (M): 20,000 @ $1.29 · Sale (S): 31,278 @ $8.82 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 31,278 @ $8.82 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 14,322 @ $7.22 | EDGAR |
| 2025-01-10 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 14,545 @ $8.22 | EDGAR |
| 2024-12-03 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 20,392 @ $4.56 | EDGAR |
| 2024-07-19 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 14,851 @ $6.47 | EDGAR |
| 2024-07-15 | 4 | Candel Therapeutics, Inc. (CADL) | Sale (S): 13,330 @ $5.97 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1923794 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →